Campbell & Co Investment Adviser’s Ocular Therapeutix OCUL Stock Holding History

Campbell & Co Investment Adviser’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-119,285	Closed	-$1.45M	–	1319
2025 Q4	$1.45M	Buy	119,285 +108,022	+959%	+$1.31M	0.07%	433
2025 Q3	$132K	Buy	+11,263	New	+$135K	0.01%	1034
2025 Q1	–	Sell	-12,071	Closed	-$103K	–	1242
2024 Q4	$103K	Buy	+12,071	New	+$118K	0.01%	1009
2024 Q2	–	Sell	-12,537	Closed	-$114K	–	1268
2024 Q1	$114K	Buy	+12,537	New	+$89K	0.01%	1059
2022 Q1	–	Sell	-18,200	Closed	-$127K	–	839
2021 Q4	$127K	Buy	+18,200	New	+$141K	0.04%	573

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Campbell & Co Investment Adviser's OCUL Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 119,285 shares — an estimated $1.45M sold.

Campbell & Co Investment Adviser first reported a position in OCUL in Q4 2021 and held it in 5 quarters. The position peaked at $1.45M in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Campbell & Co Investment Adviser reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
Campbell & Co Investment Adviser sold 119,285 Ocular Therapeutix shares in Q1 2026, an estimated $1.45M.
Campbell & Co Investment Adviser first reported a position in Ocular Therapeutix in Q4 2021 and held it in 5 quarters.
Campbell & Co Investment Adviser's Ocular Therapeutix position peaked at $1.45M in Q4 2025.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.